What is Chardan Capital's Forecast for ABUS FY2025 Earnings?

Key Points

• Chardan Capital raised its FY2025 earnings estimates for Arbutus Biopharma to ($0.18) per share, up from a previous forecast of (0.25), while maintaining a "Buy" rating on the stock with a price target of $5.00.
• Arbutus Biopharma reported a quarterly earnings beat with $0.01 per share, exceeding analyst estimates of ($0.02), and achieved revenue of $10.74 million versus expected $2.21 million.
• Institutional interest in Arbutus Biopharma has increased, with several hedge funds significantly raising their stakes in the company during the second quarter.

Arbutus Biopharma Corporation (NASDAQ:ABUS - Free Report) - Chardan Capital boosted their FY2025 EPS estimates for shares of Arbutus Biopharma in a report released on Monday, August 11th. Chardan Capital analyst K. Nakae now expects that the biopharmaceutical company will post earnings of ($0.18) per share for the year, up from their prior forecast of ($0.25). Chardan Capital has a "Buy" rating and a $5.00 price objective on the stock. The consensus estimate for Arbutus Biopharma's current full-year earnings is ($0.39) per share. Chardan Capital also issued estimates for Arbutus Biopharma's FY2026 earnings at ($0.17) EPS.

Arbutus Biopharma (NASDAQ:ABUS - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The biopharmaceutical company reported $0.01 earnings per share for the quarter, topping analysts' consensus estimates of ($0.02) by $0.03. The company had revenue of $10.74 million during the quarter, compared to analyst estimates of $2.21 million. Arbutus Biopharma had a negative net margin of 352.24% and a negative return on equity of 59.28%.

Separately, Wall Street Zen raised shares of Arbutus Biopharma from a "hold" rating to a "buy" rating in a research note on Saturday, August 9th. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, Arbutus Biopharma presently has an average rating of "Buy" and an average price target of $5.50.

Arbutus Biopharma Stock Performance

Shares of NASDAQ:ABUS traded down $0.02 during trading on Thursday, reaching $3.36. The company had a trading volume of 18,587 shares, compared to its average volume of 863,758. The firm's fifty day moving average is $3.32 and its 200 day moving average is $3.31. The firm has a market capitalization of $643.15 million, a PE ratio of -11.57 and a beta of 0.86. Arbutus Biopharma has a twelve month low of $2.70 and a twelve month high of $4.72.

Institutional Trading of Arbutus Biopharma

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Daiwa Securities Group Inc. lifted its stake in Arbutus Biopharma by 3,911.1% during the second quarter. Daiwa Securities Group Inc. now owns 15,844 shares of the biopharmaceutical company's stock valued at $49,000 after purchasing an additional 15,449 shares during the last quarter. Two Seas Capital LP lifted its stake in Arbutus Biopharma by 10.3% during the second quarter. Two Seas Capital LP now owns 10,443,317 shares of the biopharmaceutical company's stock valued at $32,270,000 after purchasing an additional 977,361 shares during the last quarter. Kennedy Capital Management LLC lifted its stake in Arbutus Biopharma by 7.1% during the second quarter. Kennedy Capital Management LLC now owns 449,179 shares of the biopharmaceutical company's stock valued at $1,388,000 after purchasing an additional 29,842 shares during the last quarter. Invesco Ltd. lifted its stake in Arbutus Biopharma by 29.8% during the second quarter. Invesco Ltd. now owns 181,084 shares of the biopharmaceutical company's stock valued at $560,000 after purchasing an additional 41,622 shares during the last quarter. Finally, Schroder Investment Management Group acquired a new stake in Arbutus Biopharma during the second quarter valued at approximately $375,000. 43.79% of the stock is owned by institutional investors and hedge funds.

Arbutus Biopharma Company Profile

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.